首页> 美国卫生研究院文献>SpringerPlus >Expression purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen
【2h】

Expression purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen

机译:基于人乳头瘤病毒16 E7抗原的重组融合蛋白的表达纯化和鉴定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A fusion protein comprising a cell penetrating and immunostimulatory peptide corresponding to residues 32 to 51 of the Limulus polyphemus protein linked to human papillomavirus (HPV)-16 E7 antigen (LALF32-51-E7) was expressed in E. coli BL21 (DE3) cells. The recombinant protein in E. coli accounted for approximately 18% of the total cellular protein and purified with a single affinity chromatographic step. Yields of approximately 38 mg purified LALF32-51-E7 per liter of induced culture was obtained with an overall 52% recovery and constitutes a promising setting for the future production and scaling-up. Purified protein was characterized as soluble aggregates with molecular weight larger than 670 kDa, which is considered an important property to increase the immunogenicity of an antigen preparation. The recombinant fusion protein LALF32-51-E7 will be a promising vaccine candidate for the treatment of HPV-16 related malignancies.
机译:在大肠杆菌BL21(DE3)细胞中表达了一种融合蛋白,该融合蛋白包含与人乳头瘤病毒(HPV)-16 E7抗原(LALF32-51-E7)连接的poly虫多phe体蛋白的32至51位残基对应的细胞穿透和免疫刺激肽。 。大肠杆菌中的重组蛋白约占总细胞蛋白的18%,并通过单亲和层析步骤进行纯化。每升诱导培养物获得约38µmg纯化的LALF32-51-E7的产量,总回收率为52%,为将来的生产和规模扩大提供了有希望的环境。纯化的蛋白质的特征是分子量大于670kkDa的可溶性聚集体,这被认为是增加抗原制剂免疫原性的重要特性。重组融合蛋白LALF32-51-E7将是治疗HPV-16相关恶性肿瘤的有前途的候选疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号